SS-31 (elamipretide): the mitochondria peptide with real trials and mixed results
SS-31 — the lab name for elamipretide, also called MTP-131 and Bendavia — is the rare biohacking peptide that went the whole way through pharmaceutical development. It has a genuinely elegant mechanism: it docks onto cardiolipin, a fat unique to the inner mitochondrial membrane, and props up the machinery that makes cellular energy. It also has something almost no research-chemical peptide can claim: a stack of real, registered human trials. The catch is what those trials found. The headline studies mostly missed. Here is the honest, graded read on what SS-31 actually does — and why the disease trials don't transplant to a healthy person buying it for energy.
- The mechanism is the real deal. SS-31 selectively binds cardiolipin — a signature lipid of the inner mitochondrial membrane — and helps the membrane keep its shape and run the energy-making chain. This is well-mapped across independent labs, not vendor marketing.
- It has a pharmaceutical pedigree almost no peptide has. Elamipretide (the same molecule) went through registered phase-2 and phase-3 human trials for heart failure, mitochondrial myopathy, Barth syndrome, and dry macular degeneration. That is serious, regulated science.
- The headline trials mostly missed. The big myopathy trial (MMPOWER-3) and the heart-failure trial (PROGRESS-HF) both failed their primary endpoints. The dry-AMD trial missed too. The one clear win was in Barth syndrome — an ultra-rare disease — where it earned a 2025 FDA accelerated approval on a muscle-strength surrogate.
- None of this proves anything for a healthy person. Every trial was run in sick patients with a specific organ failing. There is no trial showing SS-31 boosts energy or slows aging in healthy adults. The biohacker pitch runs entirely ahead of the data.
Why SS-31 stands out from the peptide crowd
Most peptides sold for “energy” and “anti-aging” share a problem: the science behind them is thin, preclinical, or non-existent. SS-31 is the striking exception. Under its drug name, elamipretide, this exact molecule was developed by a biotech company, taken through formal phase-2 and phase-3 trials, reviewed by an FDA advisory committee, and — for one ultra-rare disease — approved. That is a level of scrutiny the rest of the research-chemical peptide world never sees. When a peptide has been through that gauntlet, you don't have to guess at the evidence. You can read it.
And reading it is exactly where the story gets honest. A drug-grade pedigree cuts both ways. It means SS-31 has real mechanism and real safety data — but it also means we have well-powered, placebo-controlled trials that tell us, bluntly, where it did and didn't work. Several of the marquee trials missed their primary endpoints. A research-chemical peptide can hide behind “more studies needed.” Elamipretide can't, because the studies were done. For the wider category, see our Peptides hub.
So this is a hype-check on a serious molecule. The mechanism deserves respect. The disease trials deserve to be read precisely — wins called wins, misses called misses. And the leap from a failing heart or a rare genetic disorder to a healthy person chasing more energy deserves the scrutiny the marketing never gives it.
The mechanism: cardiolipin and the inner membrane
Here the technical vocabulary earns its place, so the jargon is allowed. SS-31 is a small synthetic peptide — one of the Szeto-Schiller peptides, named for the two scientists who designed them — built from alternating aromatic and basic amino acids. That structure does something unusual: it concentrates the peptide inside mitochondria by a thousandfold or more, where it seeks out a specific target on the inner mitochondrial membrane called cardiolipin1.
Cardiolipin is the membrane's signature lipid — it's found almost nowhere else in the cell, and it's what holds the cristae (the deep folds that pack in the energy machinery) in their proper shape. It also sits beside the electron transport chain, the assembly line that turns food and oxygen into ATP. When mitochondria are stressed or aging, cardiolipin gets oxidized and the cristae structure degrades. SS-31 docks onto cardiolipin through electrostatic and hydrophobic interactions and, in effect, stabilizes it — protecting cristae architecture and keeping cytochrome c doing its electron-carrying job rather than flipping into a damaging peroxidase2. The signal it pulls, mechanically, is “keep the power plant's walls intact so the line keeps running.”
This is the cleanest part of the entire SS-31 story, and it's why the mechanism claim grades Moderate rather than merely Emerging. It has been characterized across several independent groups — in ischemic mitochondria, in models of kidney and eye disease, and in careful biophysical work showing the peptide binds lipid bilayers and shifts membrane surface electrostatics as a core part of its action3. The honest ceiling on that grade: most of this is preclinical, and a beautifully mapped mechanism in isolated mitochondria is not the same as a felt benefit in a living person — which is precisely what the human trials went looking for.
SS-31 clearly knows how to protect a mitochondrion's inner membrane. Whether protecting that membrane changes how an organ — or a person — works is the question the trials were built to answer. The answers are mixed.
What the human trials actually show
Move from the membrane to the patient and you find something rare for a peptide: a real clinical-trial record. Elamipretide has been tested in registered, placebo-controlled studies across four very different diseases. The pattern across them is the most important thing in this article — so here it is laid out plainly, primary endpoints and all.
| Trial (year) | Population | Primary endpoint | Result |
|---|---|---|---|
| MMPOWER-3 (2023)4 | Primary mitochondrial myopathy, n=218 | 6-minute walk distance + fatigue score at 24 wks | Missed. No significant difference vs placebo on either. |
| MMPOWER-3 post-hoc (2024)5 | nDNA-mutation subgroup | 6-minute walk distance (exploratory) | Signal in nuclear-DNA subgroup only; hypothesis-generating. |
| TAZPOWER + 168-wk OLE (2024)6 | Barth syndrome, n=12 | 6MWT (crossover) → long-term strength | Crossover phase missed; open-label extension showed sustained muscle-strength and cardiac gains. |
| PROGRESS-HF (2020)7 | Heart failure, reduced EF, n=71 | Left-ventricular end-systolic volume at 4 wks | Missed. No improvement over placebo; well tolerated. |
| ReCLAIM-2 (2024)8 | Dry age-related macular degeneration | Low-luminance vision + geographic-atrophy area | Missed primaries; ~43–47% slowing of ellipsoid-zone loss (secondary). |
Start with the disappointments, because they matter most. MMPOWER-3, the pivotal phase-3 trial in primary mitochondrial myopathy (PMM — a group of genetic disorders where the energy-making machinery itself is broken), randomized 218 patients to elamipretide or placebo and measured how far they could walk in six minutes and how fatigued they felt. It missed both4. A later post-hoc analysis — meaning the researchers sliced the data after the fact — found that patients whose disease came from nuclear-DNA mutations did better than those with mitochondrial-DNA mutations5. That's a genuinely interesting lead about which patients might respond, but a post-hoc subgroup is a hypothesis for the next trial, not proof. That's why the myopathy claim grades Weak.
PROGRESS-HF tells the same cautionary story in the heart. Seventy-one patients with reduced-ejection-fraction heart failure got elamipretide or placebo for four weeks; the drug did not improve the heart's pumping volumes over placebo7. ReCLAIM-2, in dry macular degeneration, also missed its primary vision and atrophy endpoints — though it did slow the loss of a key retinal layer (the ellipsoid zone) by over 40% on imaging, a secondary signal the company is still chasing8. Across heart and eye, the pattern repeats: clean safety, a flicker on a secondary measure, and a missed primary.
Then there's the exception. In Barth syndrome — an ultra-rare genetic disease where a faulty gene cripples cardiolipin itself, putting SS-31 directly on its home turf — the picture is brighter. The randomized crossover phase of TAZPOWER didn't hit its walk-distance endpoint either, but the long open-label extension, run out to 168 weeks, showed sustained gains in knee-extensor muscle strength and cardiac measures6. That strength signal was enough that, in September 2025, the FDA granted elamipretide (brand name Forzinity) accelerated approval for Barth syndrome — its first and so far only approval. The grade here is Emerging, deliberately: the win is real, but it rests on a surrogate endpoint (muscle strength, "reasonably likely" to predict benefit), in roughly a dozen patients, in a disease tailor-made for the mechanism. It validates the biology. It does not generalize.
Disease trials vs. biohacker use
This is the section the marketing skips, so it's the one that matters. Every number above came from a sick patient — a failing heart, a genetic energy disorder, a degenerating retina. The biohacking pitch for SS-31 takes that disease data and quietly transplants it onto a healthy thirty-five-year-old who wants to feel sharper at 3 p.m. That transplant is not supported by anything in the trial record.
Here is the cleanest way to hold the two apart. This framework is not a prescription — we don't tell anyone to inject SS-31, and we give no dosing instructions. It's a map of where the evidence lives versus where the marketing wants to take it.
The entire human dataset sits in patients with a specific organ failing — Barth syndrome, primary mitochondrial myopathy, heart failure, dry AMD — studied subcutaneously in registered trials with clinician oversight. Even here, most primaries missed. The one approval is disease-specific and surrogate-based.
Extending the Barth-validated mechanism to other mitochondrial conditions is a reasonable research hypothesis — and that's all it is. Any such use belongs inside a trial or a specialist relationship, with the mixed primary-endpoint record fully understood, not a vendor's testimonial.
There is no trial of SS-31 in healthy people for energy, performance, or longevity — zero. Research-chemical sourcing adds a purity and identity unknown on top of an evidence gap. This is the claim that grades Hype, and it's the one the bottles are sold on.
We won't give you an SS-31 dose, a reconstitution recipe, or a sourcing tip. The molecule is an injectable investigational and (for one rare disease) prescription drug, not a supplement. Every legitimate use in the literature happened under medical supervision in people with diagnosed disease. If you're a healthy adult chasing energy, the trial data simply isn't about you.
The grey areas
A few honest uncertainties sit underneath the grades. The first is the missed-primary, surviving-secondary pattern. Across myopathy, heart failure, and AMD, elamipretide repeatedly failed its pre-specified primary endpoint while leaving a flicker on a secondary or post-hoc measure. That pattern is genuinely ambiguous: it can mean a real-but-small effect the trials were underpowered to catch, or it can mean noise that looks like signal once you go looking. Disciplined reading treats it as “unproven, possibly worth another trial,” not “it works.”
Second is the disease-specificity question. The clearest win came in Barth syndrome, where the defect is in cardiolipin remodeling itself — the exact target SS-31 binds. That's the best-case scenario for the mechanism, and it doesn't tell you how the peptide behaves where mitochondria are merely aging rather than genetically broken. Third is delivery and regulatory status: this is a subcutaneously injected investigational drug, now an approved prescription product for one indication — not a consumer supplement, and research-chemical versions carry purity and identity risks the trials never had to worry about. And the deepest grey area is conceptual: protecting a membrane is not the same as producing felt energy, which is exactly the gap the failed efficacy endpoints keep exposing.
What we still don't know
Three honest gaps. First, there is no trial of SS-31 in healthy people for energy, cognition, or aging — the headline consumer claim has never been tested, which is why it grades Hype7. Second, we don't know which patients respond. The MMPOWER-3 post-hoc hint that nuclear-DNA myopathy patients do better5 is intriguing but unconfirmed, and confirming it would take a fresh, prospective trial enriched for that genotype — the kind of study nobody has yet finished. Third, the Barth approval's long-term meaning is still open: it rests on a muscle-strength surrogate in a handful of patients6, and accelerated approvals carry an obligation to confirm real-world benefit over time. None of this makes SS-31 a fraud — it's a real drug with a real mechanism that earned a real, narrow approval. It makes the energy-and-longevity pitch what it is: a marketing story built on top of disease trials that were mostly negative, sold as proven, graded as anything but.
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. DOI · PMID 24117165. (Foundational review of the Szeto-Schiller peptides; SS-31 concentrates in mitochondria and selectively binds cardiolipin to protect bioenergetics.)
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. DOI · PMC3736700. (Shows SS-31 binds cardiolipin, preserves cristae and cytochrome-c electron-carrying function, restoring respiration in stressed mitochondria. Preclinical.)
- Mitchell W, Ng EA, Tamucci JD, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295(21):7452-7469. DOI · PMC7247319. (Biophysical confirmation that SS-31 binds lipid bilayers and shifts membrane surface electrostatics. Independent mechanistic work.)
- Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3):e238-e252. DOI · PMID 37268435. (Pivotal phase-3 RCT, n=218; missed both primary endpoints — 6-minute walk distance and total fatigue — vs placebo at 24 weeks.)
- Karaa A, Goldstein A, Vockley J, et al. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024;19(1):432. DOI. (Post-hoc analysis: patients with nuclear-DNA mutations walked farther than those with mtDNA mutations. Hypothesis-generating, not confirmatory.)
- Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138. DOI · PMID 38602181. (Crossover phase missed its endpoint; the 168-week open-label extension showed sustained knee-extensor strength and cardiac gains — basis for the September 2025 FDA accelerated approval of Forzinity.)
- Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437. DOI · PMID 32068002. (RCT, n=71; elamipretide did not improve left-ventricular end-systolic volume over placebo at 4 weeks. Well tolerated, primary endpoint missed.)
- Allingham MJ, Mukai S, Lad EM, et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmol Sci. 2024;4(6):100569. DOI. (Phase 2 RCT; missed primary low-luminance vision and geographic-atrophy endpoints, but slowed ellipsoid-zone loss by ~43–47% on imaging — a secondary signal only.)